Spots Global Cancer Trial Database for A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
Official Title: A Phase I/II Dose Escalation Study to Evaluating the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG2001 Tosilate Tablets in Participants With KRAS Mutated Advanced Solid Tumours
Study ID: NCT06237413
Interventions
Study Description
Brief Summary: This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chinese PLA General Hospital, Beijing, Beijing, China
Contact Details
Name: Jason Wu
Affiliation: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
